Table 1 Characteristics of study participants.

From: Responses to Quadrivalent Influenza Vaccine Reveal Distinct Circulating CD4+CXCR5+ T Cell Subsets in Men Living with HIV

  

Control

Early HIV

Chronic HIV

n

(% or IQR)

n

(% or IQR)

n

(% or IQR)

Sex

Male

14

(100.0)

8

(100.0)

8

(100.0)

Ethnicity

White British

8

(57.1)

3

(37.5)

2

(25.0)

White Other

5

(35.7)

5

(62.5)

5

(62.5)

Black British

1

(7.2)

0

(0.0)

1

(12.5)

Age years

37

(29–49)

48

(42–58)

50

(38–55)

CD4 count at vaccination, cells/µl

789

(665–1033)

609

(454–931)

CD8 count at vaccination, cells/µl

720

(558–1034)

686

(477–1350)

CD4:CD8 ratio

1

(0.9–1.4)

0.85

(0.6–1.2)

Nadir CD4 count

522

(466–734)

170

(80–410)

HIV viral load at vaccination <20 RNA copies/ml

8

(100.0)

8

(100.0)

Duration since HIV viral load <50 RNA copies/ml (months)

19

(6.8–26.5)

90

(53.0–159.0)

Self-reported influenza vaccination in last 3 years

9

(64.3)

4

(50.0)

4

(50.0)

Flu-like illness 2017–18

1

(7.1)

0

(0.0)

1

(12.5.0)

Ever smoker

4

(28.6)

2

(25.0)

4

(50.0)

Recreational drug use (ever)

0

(0.0)

2

(25.0)

2

(25.0)

Alcohol

None

1

(7.1)

1

(12.5)

3

(37.5)

<5 units/week

2

(14.3)

2

(25.0)

0

(0.0)

6–14 units/week

7

(50.0)

2

(25.0)

2

(25.0)

>14 units/ week

4

(28.6)

3

(37.5)

3

(37.5)

Hepatitis B

surface antigen positive

NA

NA

0

(0.0)

0

(0.0)

core antibody positive

NA

NA

1

(12.5)

3

(37.5)

Hepatitis C

IgG positive

NA

NA

0

(0.0)

1

(12.5)